

**Proper Muscle Gastric Cancer as Transitional State from
Early Gastric Cancer to Advanced Gastric Cancer**

Jae Gyu Kim, M.D.*, **Jun Haeng Lee, M.D.**, **Kook Lae Lee, M.D.**,
Dong Ho Lee, M.D., **Joongwon Park, M.D.***, **Hyun Chae Jung, M.D.**,
In Sung Song, M.D. and **Chung Yong Kim, M.D.**

*Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine,
Seoul; Department of Internal Medicine, Chung-Ang University College of Medicine*, Seoul, Korea*

Background/Aims: Proper muscle (PM) gastric cancer could be considered as an intermediate stage between early gastric cancer (EGC) and advanced gastric cancer (AGC) in the aspect of invasion depth, diagnostic accuracy, prognosis and macroscopic features. We investigate the characteristics of PM cancer, especially endoscopic findings. **Methods:** We analyzed the endoscopic and pathologic characteristics of PM cancer in 62 cases among 381 cases of AGC from January, 1992 through December, 1993 at Seoul National University Hospital. **Results:** The incidence of PM cancer was 16.1%. The mean size of PM cancer was 4.1 cm. It was smaller than that of non-PM cancer (0.7 cm). The diagnostic accuracy of endoscopy in PM cancer was 64.5%, which was lower than that in non-PM cancer (90.6%). AGC simulating EGC of PM cancer was 17.7% in endoscopic finding and 16.1% in pathologic finding. That of non-PM cancer was 5.5% in endoscopic finding and 2.2% in pathologic finding. Lymph node (LN) metastasis was positive in 40.3% of PM cancer and 79.3% of non-PM cancer. **Conclusions:** We consider PM cancer is a transitional state from early to non-PM advanced cancer based on the facts such as diagnostic accuracy, rate of LN metastasis, and size. **(Kor J Gastroenterol 1999;33:183 - 193)**

Key Words: PM gastric cancer, Gastric endoscopy

: 1998 8 3 , : 1998 12 7
: , 140-757, 371 65

Tel: (02) 748-9839, Fax: (02) 792-9670

37

1995
006)

(01-95-

가 가

가 가 . 381
62

가 , 가 가 , 319 .
2. .1

I , II (IIa, IIb, IIc), III

Borrmann

가
가 Borrmann , , , 8
(diffuse) (circum-
가 가 .2 ference) 가 2

가 . WHO
가
3가 , 가 80 .
4 .

가 .
가 ,
가 가

가 가 1.
24 84
50 가 140 (36.7%) 가
55.4 , 2.1:1 .

1.
50 가 27 (43.5%) 가
60 , 40
1992 1 1993 12 55.4 . 가
47 , 가 15 3.1:1 .

Table 1. Age and Sex Distribution of Patients

Age	PM		non-PM		Total
	M	F	M	F	
<30	0	1	3	1	5 (1.3)
31-40	6	1	19	15	41 (10.8)
41-50	5	2	46	19	72 (18.9)
51-60	22	5	73	40	140 (36.7)
61-70	12	4	54	25	95 (24.9)
>70	2	2	15	9	28 (7.4)
Total (%)	47 (12.4)	15 (3.9)	210 (55.1)	109 (28.6)	381 (100)

PM, proper muscle; M, male; F, female.

Table 2. Diagnostic Accuracy of Endoscopy

Type	PM (%)*	non-PM (%)*	Total (%)
AGC	40 (64.5)	289 (90.6)	329 (86.4)
EGC	11 (17.7)	17 (5.3)	28 (7.3)
a		2	
a+ c	2		
b		1	
c	7	11	
c+ a		2	
c+	1	1	
	1		
SMT	4 (6.5)	2 (0.6)	6 (1.6)
Esoca	0	4 (1.3)	4 (1.0)
Benign	7 (11.3)	7 (2.2)	14 (3.7)
Total (%)	62 (16.3)	319 (83.7)	381 (100)

*, diagnostic accuracy; AGC, advanced gastric cancer; EGC, early gastric cancer; SMT, submucosal tumor; Esoca, esophageal cancer; PM, proper muscle.

50 가 113 (35.4%) 가
60 , 40
55.2 .
가 210 , 가 109
1.9:1 (Table 1).

2.
1)
3-3.9
cm 15 (24.1%) 가 4-4.9 cm 12
(19.4%), 2-2.9 cm 5-5.9 cm 9 (14.5%)
7 cm
115 (36.0%) 가 6-6.9 cm
60 (18.8%), 5-5.9 cm 57 (17.9%)
4.1
cm, 6.7 cm .
41
(66.2%) 가 가 19 (30.6%),
가 1 .
가 158 (49.5%) 가 124 (38.9%),
19 (6.0%), 7 (2.2%)
가 11 (3.4%)
27 (43.6%), 14 (22.6%), 10 (16.1%),
가 10 (16.1%), 1 (1.6%) .
146 (45.9%),
47 (14.7%), 47 (14.7%), 33
(10.3%)가 , 35 (11.0%),
11 (3.4%) .

2)

357 (93.6%) IIC 가 가 .
 329 (86.3%), 28 (7.3%) () 2 (0.6%), 4
 62 가 51 (1.3%), 7 (2.2%) .
 (82.2%) 90.6% .
 40 (64.5%), 11 (17.7%) .
 IIC 381 329
 가 7 가 86.4% (Table 2).
 () 가 4 (6.5%) ,
 가 7 (11.3%) 3)
 1 , 1 , 1 ,
 4 . 3 cm 44.0%, 3 cm
 64.5% . 5 cm 80.7%, 5 cm 7 cm 89.5%
 319 7 cm 96.6% 가 가
 306 (95.9%) 289 가 5 cm
 (90.6%), 17 (5.3%) . 86.6% ,

Table 3. Diagnostic Accuracy of Endoscopy according to the Size of AGC

Size (cm)	PM cancer		non-PM cancer	
	AGC (%)*	Total (%)	AGC (%)*	Total (%)
- 1.9	2 (33.3)	6 (9.7)	1 (100)	1 (0.3)
2 - 2.9	4 (44.4)	9 (14.5)	4 (44.4)	9 (2.8)
3 - 3.9	9 (60.0)	15 (24.1)	28 (82.3)	34 (10.7)
4 - 4.9	9 (75.0)	12 (19.4)	38 (88.4)	43 (13.5)
5 - 5.9	8 (88.8)	9 (14.5)	54 (94.3)	57 (17.9)
6 - 6.9	4 (57.1)	7 (11.3)	53 (88.3)	60 (18.8)
7 -	4 (100)	4 (6.5)	111 (96.5)	115 (36.0)
Total (%)	40 (64.5)	62 (100)	289 (90.6)	319 (100)

*, diagnostic accuracy; AGC, advanced gastric cancer; PM, proper muscle.

Table 4. Diagnostic Accuracy of Endoscopy according to Depth of Invasion

Depth of invasion	AGC (%)*	EGC	SMT	Esoca	Benign	Total (%)
PM	40 (64.5)	11	4		7	62 (16.3)
SS	145 (86.3)	15		4	4	168 (44.1)
S	123 (94.6)	2	2		3	130 (34.1)
T4	21 (100)					21 (5.5)
Total (%)	329 (86.4)	28 (7.3)	6 (1.6)	4 (1.0)	14 (3.7)	381 (100)

*, diagnostic accuracy; AGC, advanced gastric cancer; EGC, early gastric cancer; SMT, submucosal tumor
 Esoca, esophageal cancer; SS, subserosa; S, serosa; T4, tumor penetrates through the serosa and invades th
 ontiguous structures.

Table 5. Diagnostic Accuracy of Endoscopy according to Gross Finding of AGC

Borrmann type	PM cancer		non-PM cancer	
	AGC (%)*	Total (%)	AGC (%)*	Total (%)
1	5 (71.4)	7 (11.3)	5 (100)	5 (1.6)
2	13 (100)	13 (21.0)	44 (93.6)	47 (14.7)
3	18 (58)	31 (50.0)	191 (90)	212 (66.5)
4	1 (100)	1 (1.6)	45 (93.8)	48 (15.0)
Undetermined (EGC)	3 (30)	10 (16.1)	4 (57)	7 (2.2)
Total (%)	40 (64.5)	62 (100)	289 (90.6)	319 (100)

*, diagnostic accuracy; AGC, advanced gastric cancer, EGC, early gastric cancer; PM, proper muscle.

Table 6. Cell Type and Lymph Node Involvement in AGC

Cell type	PM cancer		non-PM cancer	
	LN (+)	Total (%)	LN (+)	Total (%)
W/D	5	12 (19.4)	18	21 (6.6)
M/D	11	24 (38.7)	56	74 (24.1)
P/D	4	15 (24.2)	120	149 (46.8)
SRC	0	6 (9.7)	27	39 (12.2)
MUC	3	3 (4.8)	18	20 (6.3)
Mixed	1	1 (1.6)	8	8 (2.5)
Undetermined	1	1 (1.6)	3	5 (1.6)
ADSQ			3	3 (0.9)
Total (%)	25 (40.3)	62 (100)	253 (79.3)	319 (100)

W/D, well differentiated; M/D, moderately differentiated; P/D, poorly differentiated; SRC, signet ring cell carcinoma; MUC, mucinous carcinoma; AGC, advanced gastric cancer, LN (+), lymph node positive; ADSQ adenosquamous carcinoma; PM, proper muscle.

Table 7. Depth of Invasion and Lymph Node Involvement

Depth of invasion	Lymph node positive (%)*	Lymph node negative	Total (%)
PM	25 (40.3)	37	62 (16.3)
SS	116 (69)	52	168 (44.1)
S	116 (89.2)	14	130 (34.1)
T4	21 (100)	0	21 (5.5)
Total (%)	278 (73.0)	103 (27.0)	381 (100)

*, % of lymph node positive in each type; SS, subserosa; S, serosa; T4, tumor penetrates through the serosa and invades the contiguous structures.

7 cm 100% 75% 7 cm
5-5.9 cm 88.8%, 4-4.9 cm 96.5%가 가

5-5.9 cm '94.3%, 4-4.9 cm 88.4% (Table 5 (1.29%), 47 (14.7%), 3). 4 cm 212 (66.5%), 48 (15.0%), 7 (2.2%) . 5 cm 10 . 3 cm (16.1%) , 3 , 3 , 가 44%, 3 , 1 , 3 . 40%, 50% 7 (2.2%) , 4 . , 3 (Table 5). 4) 가 , , , 3. (T4) 가 295 (Table 4). (77.4%) 가 45 (11.8%), 23 (6%) . 91.3% 가 . 5) Borrmann 25 (40.3%) 1 , 2 , 3 , 4 100%, , ()가 7 (11.3%), 13 39.2%, 0% . (21.0%), 31 (50.0%), 1 (1.6%), 10 (16.1%) , 253 (79.3%) 90%, 79.5%, 69.2% (Table 6).

Table 8. Number of Session of Biopsies for Confirming Malignancy in AGC

Number of session	PM cancer	non-PM cancer
1	57 (91.9)	291 (91.2)
2	4 (6.5)	12 (3.8)
3		1 (0.3)
Total (%)	61 (98.4)	304 (95.3)

AGC, advanced gastric cancer; PM, proper muscle.

Table 9. Comparison of Characteristics between PM and non-PM Gastric Cancer

Characteristics	PM cancer	non-PM cancer
Differentiation of cancer		
W/D	12 (23.5%)	21 (8.6%)
M/D	24 (47.1%)	74 (30.3%)
P/D	15 (29.4%)	149 (16.1%)
Mean size	4.1 cm	6.7 cm
L/N (+)	40.3%	79.3%
AGC simulating EGC	16.1%	2.25

PM, proper muscle; AGC, advanced gastric cancer; EGC, early gastric cancer; W/D, well differentiated; M/D moderately differentiated; P/D, poorly differentiated; L/N (+), lymph node positive.

95.8% . 91.3%, 95.5%, 16.3% . 50

91.9%, 91.2% . ,911

91.9%, .101213

98.4% . , 50 가 ,

91.2%, 95.0%, 55.4 , 3.1:1

95.3% (Table 8). 8

10 , .

가 5 ,

1 . 16 (4.2%) 12 1 가 ,

, 4 2

1 , 15 . .7

4 2 가 4.1 cm 6.7

cm

8-38.3%

.278

17.7%, 16.1%

IIC 63.6%

. 1962

가

5.3%, 2.2%

X-

8

(m), 8%

(sm), (pm), (ss),

(s) .5

가

가

8.6-15%

59-88%

,268 5 가 X- ,

가 .6

Borrmann

37.6%

가 Borrmann 가 .2

44.1%, .14

34.1%

1) , 48.7-54.8% ,267
 2) (40.3% .
) 3) 79.3%
 4) . , , ,
 .14 40.3%, 69%, ,
 82.3-98.6% 89.2%, 100% 가
 .11,15-17 가 .
 84.2-90% ,15,18 가
 75% .8 가 . 5
 32.9-69.4% 70.1%
 ,15,19-21 19 ,22 가 .2
 56.2% 98.7% 가 .2
 . 64.5% , , , , ,
 가
 8 75%
 90.6% .7 가
 86.6% . 6 .
 Borrmann 3 40.3% 19 14.6%
 31 (50%)
 18 (58.0%), 6 (19.4%), (Maehara 2 48.7%, Yoshikawa Maruya-
) 3 (9.7%), 4 (12.9%) ma7 48.3%, Harrison 6 54.8% .
 .
 30% . 68.5-
 90.3% ,911 80-90%
 4 cm 가 가 가 가
 3 cm 40% ,
 3 cm
 3 cm 50%
 3 cm
 가
 295 (77.5%) 가 가
 (poorly differentiated) 55.6% 가 .
 가 가 91.3%,
 29.4% 91.9%, 91.2% .
 61.1%

64.5%, 17.7%, 11.3%,
 () 6.5% ,
 90.6%, 5.3%,
 2.2%, 1.3%, ()
 0.6%
 가 . 가 (pm),
 (ss), (s), (T4)
 64.5%,
 86.3%, 94.6%, 100% 가 .
 28 (7.4%)
 11 (17.7%), 17 (5.3%)
 . 17
 (4.5%) 10 (16.1%),
 7 (2.2%) .
 4.1 cm,
 6.7 cm .
 40.3%, 79.3% ,
 가 (pm), (ss), (s),
 (T4) 40.3%, 69.0%,
 89.2%, 100% 가 . :
 가 가 ,

: , ,

1. Weed TE, Nuessle W, Ochsner A. Carcinoma of the stomach. Why are we failing to improve survival? *Ann Surg* 1981;193:407-413.
2. Maehara Y, Anai H, Moriguchi S, Watanabe A, Tsujitani S, Sugimachi K. Gastric carcinoma invading muscularis propria and macroscopic appearance. *Eur J Surg Oncol* 1992;18:131-134.

3. Davis GR. Neoplasm of the stomach. In: Sleisenge MH, Fordtran JS, ed. *Gastrointestinal disease: pathophysiology, diagnosis and management*. Volume 1. 5th ed. Philadelphia: WB Saunders, 1993:766-767.
4. Eckardt VF, Willems D, Kanzler G, Remmele W, Bettendorf U, Paulus W. Eighty months persistence of poorly differentiated early gastric cancer. *Gastroenterology* 1984;87:719-724.
5. Japanese Research Society for Gastric Cancer. The general rule for the gastric cancer study in surgery and pathology. *Jpn J Surg* 1981;11:127-139.
6. Harrison JC, Dean PJ, Vander Zwaag R, el-Zeky F, Wruble LD. Adenocarcinoma of the stomach with invasion limited to the muscularis propria. *Hum Pathol* 1991;22:111-117.
7. Yoshikawa K, Maruyama K. Characteristics of gastric cancer invading to the proper muscle layer with special reference to mortality and cause of death. *Jpn J Clin Oncol* 1985;15:499-503.
8. . . . pm
 1982;14:91-96.
9. , , , , , .
 1981;13:17-23.
10. , , .
 183
 1986;18:117-121.
11. , , , .
 가 -
 1975;18:533-538.
12. .
 1974;17:906-911.
13. , , , . 1000
 1976;19:
 1064-1070.
14. .
 1993;13:898-907.
15. . X
 1979;11:33-38.
16. Winawer SJ, Sherlock P, Hajdu SI. The role of upper gastrointestinal endoscopy in patients with

- cancer. *Cancer* 1976;37:440-448.
17.
1988;35:404-413.
 18. Winawer SJ, Posner G, Lightdale CJ, Sherlock P, Melamed M, Fortner JG. Endoscopic diagnosis of advanced gastric cancer: factors influencing yield. *Gastroenterology* 1975;69:1183-1187.
 19. , , .
가 . 1989;21:
790-797.
 20. , , , .
. 1991;23:428-435.
 21. , , , , , .
 22. Hirota T, Shimoda T, Sano R. Pathology of pm gastric cancer: relationship between early and advanced cancer. *Stomach Intestine* 1976;11:837- 846.
 23. Yoshimori M, Yoshida S, Nakamura K, Oguro Y. Relationship between early and advanced gastric cancers: retrospective follow-up study of gastric cancer. *Jpn J Clin Oncol* 1978;8:3-12.
 24. Matsusaka T, Kodama Y, Soejima K, et al. Recurrence in early gastric cancer: a pathologic evaluation. *Cancer* 1980;46:168-172.
 25. Tsukuma H, Mishima T, Oshima A. Prospective study of "early" gastric cancer. *Int J Cancer* 1983 31:421-426.
-